Clinical Trials Currently Enrolling at Banner Sun Health Research Institute

Banner Sun Health Research Institute conducts many trials and studies, but most commonly we conduct Parkinson's disease trials and Alzheimer's studies. Below is a list of some of our ongoing clinical trials. To get more information about clinical trials, please call (623) 832-6500. Other trials can also be found online at Centerwatch.com.

If you are interested participating in one of the many clinical trials at Banner Health, please complete the form here.

Parkinson's Disease Trials

• PPMI 2.0 Clinical -Establishing a Deeply Phenotyped PD Cohort (PPMI) (NCT04477785)
• A Study to Assess the Safety of BIIB122 Tablets and if it Can Slow the Worsening of Early-Stage Parkinson's Disease in Participants Between the Ages of 30 and 80 (LUMA) (NCT05348785)

Alzheimer's Disease Trials

• A Pivotal Study of Sensory Stimulation in Alzheimer's Disease (Hope Study, CA-0011) (Hope) (NCT05637801)
• AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid (NCT 04468659)
• A Trial to Evaluate the Efficacy and Safety of PQ912 in Patients With Early AD (VIVA-MIND) (NCT03919162)
• Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants with Tardive Dyskinesia (Neurocrine TD) (NCT05859698)
• Alzheimer's Disease Neuroimaging Initiative 4 (ADNI4) (NCT05617014)
• [18F] PI-2620 Phase 3 Histopathological Study (LMT) (NCT05641688)
• A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (NCT05399888)
• A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People with Alzheimer's Disease (Novo Nordisk 7519) (NCT05891496)

Lewy Body Dementia

• Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies (COG1201) (NCT05225415)
• RewinD-LB - Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies (EIP-DLB) (NCT05869669)